Sungho Lee

Sungho Lee

Auto-generated profile, based on publicly available information

Sungho Lee

Department of Intelligence and Information Seoul National University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in The American Journal of Pathology
Verified
Journal Article
Closed access
SLSungho Lee
Sungho Lee
NVNicholas H. Varvel
Nicholas H. Varvel
MKMegan E. Konerth
Megan E. Konerth
GXGuixiang Xu
Guixiang Xu
ACAstrid E. Cardona
Astrid E. Cardona
BLBruce T. Lamb
Bruce T. Lamb

10 September 2014 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SLSungho Lee
Sungho Lee
GXGuixiang Xu
Guixiang Xu
TJTaylor R. Jay
Taylor R. Jay
SBSabina Bhatta
Sabina Bhatta
KKKi-Wook Kim
Ki-Wook Kim
BLBruce T. Lamb
Bruce T. Lamb
Several Alzheimer's disease (AD) risk genes are specifically expressed by microglia within the CNS. However, the mechanisms by which microglia regulate the pathological hallmarks of AD—extracellular deposition of β-amyloid (Aβ) and intraneuronal hyperphosphorylation of microtubule-associated protein tau (MAPT)—remain to be established. Notably, deficiency for the microglial CX3CR1 receptor has opposing effects on Aβ and MAPT pathologies. CX3CL1, the neuronally derived cognate ligand for CX3CR1, signals both in membrane-anchored and soluble forms. In this study, we sought to determine the relative contribution on membrane-anchored versus soluble CX3CL1 in regulating the microglia-mediated amelioration of Aβ pathology, as well as provide insight into the potential downstream microglial-based mechanisms. As expected, CX3CL1 deficiency reduced Aβ deposition in APPPS1 animals in a similar manner to CX3CR1 deficiency. Surprisingly, however, CX3CL1-deficient APPPS1 animals exhibited enhanced neuronal MAPT phosphorylation despite reduced amyloid burden. Importantly, neither of these phenotypes was altered by transgenic expression of the soluble CX3CL1 isoform, suggesting that it is the membrane-anchored version of CX3CL1 that regulates microglial phagocytosis of Aβ and neuronal MAPT phosphorylation. Analysis of transcript levels in purified microglia isolated from APPPS1 mice with the various CX3CL1/CX3CR1 genotypes revealed increased expression of inflammatory cytokines and phagocytic markers, which was associated with activation of p38 mitogen-activated protein kinase and Aβ internalization within microglia. Together, these studies challenge the “frustrated phagocytosis” concept and suggest that neuronal–microglial communication link the two central AD pathologies.

8 January 2019 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
PKPatrick J. Karas
Patrick J. Karas
SLSungho Lee
Sungho Lee
JJJoohi Jimenez-Shahed
Joohi Jimenez-Shahed
WGWayne K. Goodman
Wayne K. Goodman
AVAshwin Viswanathan
Ashwin Viswanathan
Sameer A. ShethSameer A. Sheth
Sameer A. Sheth
Obsessive compulsive disorder (OCD) is a common, disabling psychiatric disease characterized by persistent, intrusive thoughts and ritualistic, repetitive behaviors. Deep brain stimulation (DBS) is thought to alleviate OCD symptoms by modulating underlying disturbances in normal cortico-striato-thalamo-cortical (CSTC) circuitry. Stimulation of the ventral portion of the anterior limb of the internal capsule (ALIC) and underlying ventral striatum (“ventral capsule/ventral striatum” or “VC/VS” target) received U.S. FDA approval in 2009 for patients with severe, treatment-refractory OCD. Over the decades, DBS surgical outcome studies have led to an evolution in the electrical stimulation target. In parallel, advancements in neuroimaging techniques have allowed investigators to better visualize and define CSTC circuits underlying the pathophysiology of OCD. A critical analysis of these new data suggests that the therapeutic mechanism of DBS for OCD likely involves neuromodulation of a widespread cortical/subcortical network, accessible by targeting fiber bundles in the ventral ALIC that connect broad network regions. Future studies will include advances in structural and functional imaging, analysis of physiological recordings, and utilization of next-generation DBS devices. These tools will enable patient-specific optimization of DBS therapy, which will hopefully further improve outcomes.

19 April 2017 in Global Spine Journal
Verified
Journal Article
Open access
STSara E. Thompson
Sara E. Thompson
ZSZachary A. Smith
Zachary A. Smith
WHWellington K. Hsu
Wellington K. Hsu
ANAhmad Nassr
Ahmad Nassr
TMThomas E. Mroz
Thomas E. Mroz
KRK. Daniel Riew
K. Daniel Riew
Study Design: A multicenter, retrospective review of C5 palsy after cervical spine surgery. Objective: Postoperative C5 palsy is a known complication of cervical decompressive spinal surgery. The goal of this study was to review the incidence, patient characteristics, and outcome of C5 palsy in patients undergoing cervical spine surgery. Methods: We conducted a multicenter, retrospective review of 13 946 patients across 21 centers who received cervical spine surgery (levels C2 to C7) between January 1, 2005, and December 31, 2011, inclusive. P values were calculated using 2-sample t test for continuous variables and χ2 tests or Fisher exact tests for categorical variables. Results: Of the 13 946 cases reviewed, 59 patients experienced a postoperative C5 palsy. The incidence rate across the 21 sites ranged from 0% to 2.5%. At most recent follow-up, 32 patients reported complete resolution of symptoms (54.2%), 15 had symptoms resolve with residual effects (25.4%), 10 patients did not recover (17.0%), and 2 were lost to follow-up (3.4%). Conclusion: C5 palsy occurred in all surgical approaches and across a variety of diagnoses. The majority of patients had full recovery or recovery with residual effects. This study represents the largest series of North American patients reviewed to date.

1 July 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KVKulandaivelu S. Vetrivel
Kulandaivelu S. Vetrivel
XZXulun Zhang
Xulun Zhang
XMXavier Meckler
Xavier Meckler
HCHaipeng Cheng
Haipeng Cheng
SLSungho Lee
Sungho Lee
GTGopal Thinakaran
Gopal Thinakaran
Cerebral deposition of β-amyloid (Aβ) peptides is a pathological hallmark of Alzheimer disease. Intramembranous proteolysis of amyloid precursor protein by a multiprotein γ-secretase complex generates Aβ. Previously, it was reported that CD147, a glycoprotein that stimulates production of matrix metalloproteinases (MMPs), is a subunit of γ-secretase and that the levels of secreted Aβ inversely correlate with CD147 expression. Here, we show that the levels and localization of CD147 in fibroblasts, as well as postnatal expression and distribution in brain, are distinct from those of integral γ-secretase subunits. Notably, we show that although depletion of CD147 increased extracellular Aβ levels in intact cells, membranes isolated from CD147-depleted cells failed to elevate Aβ production in an in vitro γ-secretase assay. Consistent with an extracellular source that modulates Aβ metabolism, synthetic Aβ was degraded more rapidly in the conditioned medium of cells overexpressing CD147. Moreover, modulation of CD147 expression had no effect on ϵ-site cleavage of amyloid precursor protein and Notch1 receptor. Collectively, our results demonstrate that CD147 modulates Aβ levels not by regulating γ-secretase activity, but by stimulating extracellular degradation of Aβ. In view of the known function of CD147 in MMP production, we postulate that CD147 expression influences Aβ levels by an indirect mechanism involving MMPs that can degrade extracellular Aβ.

1 April 2016 in Journal of Neurotrauma
Verified
Journal Article
Closed access
OKOlga N Kokiko-Cochran
Olga N Kokiko-Cochran
LRLena Ransohoff
Lena Ransohoff
MVMike Veenstra
Mike Veenstra
SLSungho Lee
Sungho Lee
MSMaha Saber
Maha Saber
BLBruce T. Lamb
Bruce T. Lamb
Traumatic brain injury (TBI) has acute and chronic sequelae, including an increased risk for the development of Alzheimer's disease (AD). TBI-associated neuroinflammation is characterized by activation of brain-resident microglia and infiltration of monocytes; however, recent studies have implicated beta-amyloid as a major manipulator of the inflammatory response. To examine neuroinflammation after TBI and development of AD-like features, these studies examined the effects of TBI in the presence and absence of beta-amyloid. The R1.40 mouse model of cerebral amyloidosis was used, with a focus on time points well before robust AD pathologies. Unexpectedly, in R1.40 mice, the acute neuroinflammatory response to TBI was strikingly muted, with reduced numbers of CNS myeloid cells acquiring a macrophage phenotype and decreased expression of inflammatory cytokines. At chronic time points, macrophage activation substantially declined in non-Tg TBI mice; however, it was relatively unchanged in R1.40 TBI mice. The persistent inflammatory response coincided with significant tissue loss between 3 and 120 days post-injury in R1.40 TBI mice, which was not observed in non-Tg TBI mice. Surprisingly, inflammatory cytokine expression was enhanced in R1.40 mice compared with non-Tg mice, regardless of injury group. Although R1.40 TBI mice demonstrated task-specific deficits in cognition, overall functional recovery was similar to non-Tg TBI mice. These findings suggest that accumulating beta-amyloid leads to an altered post-injury macrophage response at acute and chronic time points. Together, these studies emphasize the role of post-injury neuroinflammation in regulating long-term sequelae after TBI and also support recent studies implicating beta-amyloid as an immunomodulator.